Savara (NASDAQ:SVRA) vs. PMV Pharmaceuticals (NASDAQ:PMVP) Financial Contrast

Savara (NASDAQ:SVRA) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Volatility and Risk

Savara has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.

Profitability

This table compares Savara and PMV Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Savara and PMV Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1	0	6	1	2.88
PMV Pharmaceuticals	1	0	1	1	2.67

Savara currently has a consensus target price of $10.14, indicating a potential upside of 90.30%. PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 371.70%. Given PMV Pharmaceuticals’ higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Savara.

Institutional & Insider Ownership

87.9% of Savara shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Savara and PMV Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84 million	($0.56)	-9.52
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.71

Savara is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

PMV Pharmaceuticals beats Savara on 8 of the 11 factors compared between the two stocks.

About Savara

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.